PROMOMED company has received permission to produce a medicine for diabetes mellitus "quot;Quincent" based on semaglutide

29.12.2023

Corporate
Medicines
Industry development

The Russian government has issued an order authorizing PROMOMED Group of Companies to use inventions protected by patents of the Danish company Novo Nordisk related to a semaglutide-based diabetes drug. PROMOMED has developed and is producing the drug Quincenta (semaglutide), which is used in the treatment of diabetes mellitus, including in patients with obesity and overweight or cardiovascular diseases.

A medicine based on semaglutide can be called the gold standard for the treatment of diabetes mellitus. It is important that this advanced therapy is now available to all patients who need such a drug - PROMOMED has already introduced the drug "Quincenta" into civilian circulation, more than 120 thousand packages have been shipped. PROMOMED has sufficient production facilities and reserves of the drug "Quincenta" to fully meet the annual needs of patients in Russia. The group's facilities also allow it to supply Quincent to foreign markets. 

It should be noted that this decision is important, as it is aimed at helping patients in need of life-saving therapy and supports the country's national pharmaceutical safety strategy.

Get the most interesting news and publications first!

Sent successfully!

Pharmacovigilance

Press office

To request a press release or interview, please contact our press office